Multivariable Results from Cox Proportional Hazards Regression Analyses of Predictors of Virologic Rebound.

<p>Abbreviations: HR, hazard ratio; CI, confidence interval; T0, time of first viral load result using the ultrasensitive Taqman assay (study entry); NNRTI, non-nucleoside reverse transcriptase inhibitor; ART, antiretroviral therapy.</p>a<p>N = 773 (5 cases with missing demographic or laboratory values).</p>b<p>Significant association, P<0.05.</p>c<p>N = 540, including 180 subjects with VL <48 copies, and 360 subjects with undetectable VL propensity score-matched to the <48 group. Only effects of the T0 VL group were compared as propensity score-matching adjusted for baseline differences between cohorts.</p

Baseline (T0) Study Population Characteristics.

<p>Abbreviations: T0, time of first viral load result using the ultrasensitive Taqman assay (study entry); TND, target not detected; NNRTI, non-nucleoside reverse transcriptase inhibitor.</p>a<p>4 missing values, N = 774.</p>b<p>Number and percent within T0 viral load group.</p>c<p>Includes protease inhibitor, integrase inhibitor-based and other regimens.</p>d<p>Includes 180 subjects with VL <48 copies, and 360 subjects with undetectable VL propensity score-matched to the <48 group.</p>e<p>Mean CD4 counts were identical after propensity matching.</p

Reservoir quantification and rebound dynamics for the two “Boston patients”.

<p>Reservoir quantification and rebound dynamics for the two “Boston patients”.</p

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

<p>Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV</p

Summary of model of reservoir dynamics and rebound.

<p>a) Patients on fully suppressed ART are given an additional intervention to reduce the LR size. The stochastic model of viral dynamics following ART-interruption tracks both latently infected resting CD4⁺ T cells (rectangles) and productively infected CD4⁺ T cells (ovals). Viral rebound occurs if at least one remaining latently infected cell survives long enough to activate and produce a chain of infection events leading to detectable viremia. b) Model predictions for probability that the LR is cleared. Clearance occurs if all cells in the LR die before a reactivating lineage leads to viral rebound. c) Predicted median viral rebound times among patients who do not clear the infection. d) Survival curves (Kaplan-Meier plots) show the percentage of patients predicted to have not yet experienced viral rebound, as a function of the time after treatment interruption.</p

Predicting and interpreting the outcomes of treatment interruption when the reservoir reduction is unknown.

<p>A Bayesian approach is used to integrate information from reservoir assays with model predictions to relate the time absence or occurrence of viral rebound following ART-interruption to the remaining reservoir size. a) Prior distribution for the (unknown) reservoir reduction. We use as a prior the post-test likelihood for each reservoir size after a negative viral outgrowth assay (see <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005535#sec017" target="_blank">Methods</a>). b) The posterior probability for the LR reduction, given that <i>rebound has occurred</i>, using the posterior median (and 95% credible interval). c)The posterior probability for the LR reduction, as a function of the current time off treatment <i>without</i> rebound, using the posterior median (and 95% credible interval). d) The probability of ultimate reservoir clearance (cure) as a function of the current time off treatment <i>without</i> rebound. The initial cure probability is near zero and again takes over a decade to reach high values. Note that the reservoir reduction may either refer to the decrease in the number of latently infected cells in a given patient after administering a latency-reducing therapy, or, the factor by which initial reservoir seeding was limited, relative to a typical chronically infected patient.</p

Impact of assay sensitivity and time between viral load samples on potential reservoir reseeding during rebound.

<p>a) We estimate how much re-seeding of the LR could occur between when viral rebound occurs and when it is detected, using a method for estimating LR sizes previously validated during acute infection [<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005535#ppat.1005535.ref026" target="_blank">26</a>]. We assume the LR size is very small (approx. zero) before interruption, though if it is larger these values represent the increase in size. LR size is measured as the frequency of infectious provirus among resting CD4⁺ T cells (IUPM = infectious units per million). We consider assay detection limits of 2 (dark blue), 20 (cyan), and 200 (red) copies/ml, and assume a worst-case scenario where viral load is just below this value at the last undetected sampling point. Smaller figures on the right show the b) viral load and c) CD4 count trajectories over time that generated the IUPM measurements in the larger figure. Time is measured relative to the time viral load reached the detection limit, and we assume detection does not occur until this value is surpassed.</p

The optimal frequency of viral load sampling during supervised treatment interruptions.

<p>a) We calculate sampling times such that the probability of viral rebound between each test is equal and small—either 5% (dark blue line) or 10% (red line). These times are then transformed into intervals and expressed as the number of recommended samples per month. For these results we use the same prior distribution for the reservoir size as <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005535#ppat.1005535.g002" target="_blank">Fig 2a</a>. The recommended frequency starts off low, before jumping to high values, because even without any reservoir-reduction, rebound rarely occurs within the first two weeks in patients who have been on suppressive cART. More frequent initial monitoring may be advisable if it is suspected that patients were not suppressed before interruption. b) A simplified sampling scheme that involves only regular intervals and assures less than 5% chance of failure between measures.</p

Schematic of potential cell and viral dynamics during hematopoietic stem cell transplant with suppressive cART.

<p>Solid circles: recipient cells. Open circles: donor cells. Red: HIV⁺ cells. The recipient patient starts out with high levels of CD4⁺ T cells, a small fraction of which are latently infected with HIV. Following conditioning chemotherapy, recipient cell levels drop. When donor cells are transplanted, recipient cells continue to decline as donor cells increase in number. If any ongoing viral replication occurs during engraftment, donor cells may become HIV-infected. Without new infections, the latent reservoir size should decrease proportionally to the frequency of recipient cells, but new infection of donor cells may quell this decrease. Viral blips may occur during transplant, perhaps due to imperfect cART adherence or immune-modulated viral re-activation. If cART is interrupted, then any remaining latently-infected cells—either from the recipient or donor—may reactivate and lead to viral rebound.</p

The required trial size to accurately and precisely estimate the LR-reduction.

<p>For each possible known LR-reduction (x-axis), we determine the number of patients in a trial (y-axis) needed so that at least 95% of trials of this size would result in 95% credible intervals for the estimated reduction that contain the true value and are less than 1 log wide. We sample hypothetical patients using our model, either with identical best-estimated parameter values (dark blue line), or allow interpatient variation from a range of possible values (cyan line); see distributions and data sources described in [<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005535#ppat.1005535.ref010" target="_blank">10</a>] and <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005535#ppat.1005535.s001" target="_blank">S1 Text</a>). We assume that all patients in the trial experience the same reservoir reduction (with only binomial variation in the actual number of cells remaining), and that patients are followed for a maximum of 10 years.</p